Cunningham Panel Translational Psychiatry

Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism

Published: Translational Psychiatry

Study results suggest that the autoimmune targets in the Cunningham Panel™ can predict IVIG treatment response in a subset of autism patients.

Cunningham Panel Sunny’s Story

Case Report: PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms: Treatment, Resolution, and Recovery

Published: Frontiers in Psychiatry

A previously asymptomatic, healthy 7-year-old girl experienced an abrupt onset of several physical, neurological, and psychiatric symptoms increasing in intensity over a 3-week period.

Cunningham Panel Frontiers in Psychiatry

Autoantibody biomarkers for basal ganglia encephalitis in Sydenham chorea and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections

Published: Frontiers in Psychiatry

Dr. Madeleine Cunningham, co-author, reviews the utilization of antineuronal antibodies (measured with the Cunningham Panel™) as biomarkers for infection-triggered, autoimmune, basal ganglia encephalitis and the significance of the CaMKinase II.

Cunningham Panel Brain, Behavior & Immunity

Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection

Published: Brain, Behavior & Immunity

Cunningham Panel™ results indicate Lyme disease may trigger an autoimmune dysfunction, as elevated neuronal autoantibodies have been associated with persistent symptoms.

Cunningham Panel Evaluation

Evaluation of the Cunningham Panel™ in PANDAS and PANS: Changes in antineuronal antibody titers parallel changes in patient symptoms

Published: Journal of Neuroimmunology

Dr. Craig Shimasaki, CEO and President, Moleculera Labs, reviews findings from the study, which describes the sensitivity, specificity and accuracy of the Cunningham Panel™ for patients with PANS and PANDAS.

Cunningham Panel Case Reports in Psychiatry

An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment

Published: Case Reports in Psychiatry

An atypical presentation of Pediatric Acute Neuropsychiatric Syndrome responding to plasmapheresis treatment. Case review: Dr. Shimasaki

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.